Claremont Biosolutions, LLC

Upland, CA 91786

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $4.3MM
First Award Date 08/01/09
Most Recent Award Date 09/01/15

Key Personnel

Last Name Name Awards Contact
Boyle David Scott Boyle 3
Doebler Robert William Doebler 3
Irvine Bruce D Irvine 4
Niemz Angelika Niemz 3
FERGUSON TANYA MARIE FERGUSON 1
BROWN MARK T BROWN 2

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): The overall market size for nucleic acid sample preparation for research and the four applied markets of food testing, cosmetics, veterinary medicine, and molecular diagnostics total $5.7 billion in 2012 and with a moderate CAGR of 10 % is projected to $9.7 billion in 2016 12-5. Extraction of nucleic acids fr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-335
Budget: 09/01/14 - 08/31/15

Summary The overall market size for nucleic acid sample preparation for research and the four applied markets of food testing, cosmetics, veterinary medicine, and molecular diagnostics total $5.7 billion in 2012 and with a moderate CAGR of 10 % is projected to $9.7 billion in 2016 12-5. Extraction of nucleic acids from tissue has become a crowde...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): The primary goal of this proposed project is to develop a point-of-care diagnostic assay and platform for the detection of Clostridium difficile from human stool. Two additional goals are to detect the hypervirulent strain of C. difficile B1/NAP/027 and to detect C. difficile spores from swabs of medical devi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): The primary goal of this proposed project is to develop a point-of-care diagnostic assay and platform for the detection of Clostridium difficile from human stool. Two additional goals are to detect the hypervirulent strain of C. difficile B1/NAP/027 and to detect C. difficile spores from swabs of medical devi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/01/12 - 06/30/13

DESCRIPTION (provided by applicant): The primary goal of this proposed project is to develop a point-of-care diagnostic assay and platform for the detection of Clostridium difficile from human stool. Two additional goals are to detect the hypervirulent strain of C. difficile B1/NAP/027 and to detect C. difficile spores from swabs of medical devi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-135
Budget: 08/01/10 - 07/31/11

DESCRIPTION (provided by applicant): Antibiotic treatment of infections with harmful bacteria can destroy the normal colonic flora, and increase the patient's susceptibility to Clostridium difficile-associated disease (CDAD). Pathogenic strains of C. difficile commonly produce two large clostridial toxins, A (TcdA) and B (TcdB), responsible for ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-135
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): Antibiotic treatment of infections with harmful bacteria can destroy the normal colonic flora, and increase the patient's susceptibility to Clostridium difficile-associated disease (CDAD). Pathogenic strains of C. difficile commonly produce two large clostridial toxins, A (TcdA) and B (TcdB), responsible for ...